PULSE BIOSCIENCES, INC. 8-K

What Happened Pulse Biosciences, Inc. filed an 8-K on April 7, 2026 announcing the first patient enrollments in its NANOPULSE-AF prospective, multicenter, pivotal IDE clinical study. The study is evaluating the company’s nPulse™ Cardiac Catheter System for treating recurrent, drug‑resistant, symptomatic paroxysmal atrial fibrillation. The first seven patients were treated at St. Bernards Medical Center in Jonesboro, Arkansas by Devi Nair, MD, Principal Investigator of the Arrhythmia Research Group.

Key Details

• Study enrollment target: approximately 215 participants across multiple clinical sites.
• First patients treated: seven patients at St. Bernards Medical Center (Jonesboro, AR).
• Endpoints/timing: primary endpoints to be assessed at 6 and 12 months post‑ablation to measure procedural success and safety.
• Announcement: press release issued April 7, 2026 publicizing the enrollment milestone.

Why It Matters This enrollment milestone marks the start of a pivotal IDE trial, a key step in clinical development that will generate the safety and effectiveness data investors will watch closely. The 6‑ and 12‑month primary endpoint assessments define near‑term milestones; progress against the ~215‑patient enrollment goal and subsequent outcome data are likely to be material events for the company’s regulatory path and future commercial prospects.